Zacks Investment Research on MSN
Earnings preview: Pfizer (PFE) Q4 earnings expected to decline
Wall Street expects a year-over-year decline in earnings on lower revenues when Pfizer (PFE) reports results for the quarter ...
NEW YORK -- A course of pills developed by Pfizer can slash the risk of being hospitalized or dying from COVID-19 by 89% if taken within three days of developing symptoms, according to results ...
Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings supporting a compelling value thesis. See why.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results